FLT3-TKD mutations do not exert an independent prognostic impact [39], albeit with some conflicting results [92,93], possibly depending on the context (i.e., CBF, NPM1 vs. KMT2A-PTD-positive AML) [20,90,94]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.